The BMJ Establishes an Independent Panel to Review Statin Articles
Draft terms of reference and membership of panel now on bmj.com
An independent panel has now been established to review two articles published in The BMJ by John Abramson and colleagues and Aseem Malhotra. Last week, the authors withdrew a statement in their articles about the side effects of statins after it was found to be incorrect.
The draft terms of reference and membership of the panel are now available on bmj.com.
The panel will be chaired by Iona Heath, former chair of the Royal College of General Practitioners and of The BMJ’s ethics committee, and will have six other members:
Stephen Evans, professor of pharamcoepidemiology at the London School of Hygeine and Tropical Medicine
Curt Furberg, professor emeritus of public health sciences at Wake Forest University School of Medicine, North Carolina
Julia Hippisley-Cox, professor of epidemiology and general practice at the University of Nottingham
Harlan Krumholz, Harold H. Hines Jr. professor of medicine (cardiology) and professor of investigative medicine and of public health (health policy) at Yale School of Medicine
Cynthia Mulrow, senior deputy editor at Annals of Internal Medicine and adjunct professor of medicine at Texas University of Health Science Center
Paul Wilks, vice president of innovation, Patients Like Me
The panel’s remit will be to consider whether either or both articles should be retracted and to review and comment on the process by which the articles were published. The panel will also review and comment on how criticisms and complaints against the articles were raised, and how the journal responded.
The panel will then make recommendations to The BMJ's editor in chief in a report by 31 July 2014 that will be published on bmj.com.
To ensure full accountability and transparency, all submissions to the panel and all documents used by the panel will be placed in the public domain on bmj.com, either at the time of submission or as part of the panel's final report.
Panel members and all those submitting information to the panel will also make full declarations of their interests, which will also be published on bmj.com.
Read full details here: http://www.bmj.com/about-bmj/independent-statins-review-panel
To comment on the draft please email [email protected] by Friday 23 May 2014
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
